Randomized, open-label study of the short-term pharmacokinetics of oral magnesium oxide in healthy volunteers.

En randomiserad öppen farmakokinetisk studie undersökte upptag efter en engångsdos magnesiumoxid. Systemisk exponering ökade inte markant, vilket pekar på dålig biotillgänglighet för magnesiumoxid. They did not estimate half-life, AUC0-infinity, clearance or mean residence time because the 12-hour samples did not show a clear terminal log-linear phase. The higher dose did not produce a proportional increase in Cmax or AUC, and incremental exposure measures were also similar between doses. Tmax was shorter with 2,000 mg than with 750 mg (p=0.025). Both doses were tolerated without serious adverse events or gastrointestinal side effects. This is an acute absorption study, not an efficacy trial. It shows that more magnesium oxide did not translate into proportionately greater measured systemic exposure over 12 hours. The abstract explicitly says these exploratory pharmacokinetic results should not be extrapolated to clinical efficacy or perioperative dosing.

Oral magnesium oxide showed non-proportional systemic exposure across the 750-2,000 mg range during the 12-hour observation period.